Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Macugen (Pegaptanib Sodium)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Macugen (Pegaptanib Sodium). Displaying page 1 of 1.
    EudraCT Number: 2009-017540-13 Sponsor Protocol Number: Start Date*: 2010-07-27
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A Phase IV Open-Labelled Prospective Pilot Study of Intravitreal Macugen (pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME study)
    Medical condition: Ischaemic diabetic macular oedema.
    Disease: Version SOC Term Classification Code Term Level
    12 10057915 diabetic macular oedema SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001460-32 Sponsor Protocol Number: EOP1013B Start Date*: 2006-02-15
    Sponsor Name:Pfizer Inc
    Full Title: A phase 2/3 randomized, controlled, double-masked, multicenter, comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of 0.3 mg pegaptanib sodium ...
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) AT (Completed) DK (Completed) ES (Completed) GB (Completed) PT (Completed) BE (Completed) DE (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-004296-11 Sponsor Protocol Number: EOP 1010B Start Date*: 2005-07-12
    Sponsor Name:(OSI) Eyetech Pharamceuticals Inc
    Full Title: An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration (AMD).
    Medical condition: Exudative Age Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8 10025411 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005945-39 Sponsor Protocol Number: HLS03/2007 Start Date*: 2008-01-30
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Phase II open label study of Pegaptanib sodium on patients with subfoveal choroidal neovascularization caused by pathologic myopia.
    Medical condition: Patients with choroidal neovascularization secondary to pathologic myopia.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10060823 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020946-80 Sponsor Protocol Number: A5751036 Start Date*: 2011-03-01
    Sponsor Name:Pfizer Inc
    Full Title: A PHASE IIIB, ONE YEAR, OPEN LABEL, MULTICENTRE, NONCOMPARATIVE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF INTRAVITREAL PEGAPTANIB SODIUM INJECTION IN SUBJECTS WITH DIABETIC MACULAR EDEMA (DME)
    Medical condition: Subjects with type I or type II diabetes with diabetic macular edema (DME) with proliferative or non proliferative diabetic retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) ES (Completed) DE (Completed) FI (Completed) AT (Prematurely Ended) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000705-30 Sponsor Protocol Number: KONK1001 Start Date*: 2007-05-15
    Sponsor Name:Moorfields Eye Hospital Foundation Trust
    Full Title: efficacy of pegaptanib sodium (macugen) on uveitic cystoid macular oedema: an exploratory study
    Medical condition: uveitic cystoid macular oedema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058202 Cystoid macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016760-36 Sponsor Protocol Number: CC-02-2009 Start Date*: 2010-02-05
    Sponsor Name:AIBILI
    Full Title: Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy)...
    Medical condition: Proliferative Diabetic Retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006795-10 Sponsor Protocol Number: FPH-Macugen08 Start Date*: 2008-08-15
    Sponsor Name:Frimley Park Hospital NHS Foundation Trust
    Full Title: A randomised controlled trial of efficacy of Pegaptanib sodium in the prevention of proliferative diabetic retinopathy
    Medical condition: Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054109 Non-proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004514-32 Sponsor Protocol Number: A5751017 Start Date*: 2006-03-07
    Sponsor Name:
    Full Title: A 102-Week, open label, multicenter trial to investigate the efficacy of macugen for the preservation of visual function in subjects with neovascular age-related macular degeneration (AMD) and to a...
    Medical condition: Age related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) AT (Prematurely Ended) GB (Completed) ES (Completed) CZ (Prematurely Ended) BE (Completed) DK (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000722-31 Sponsor Protocol Number: EOP1014 Start Date*: 2006-08-17
    Sponsor Name:(OSI) Eyetech, Inc
    Full Title: An Exploratory randomized, double-masked, multi-center, multi-dose comparative trial, in parallel groups, to explore the safety and efficacy of three different doses of intravitreous injections of ...
    Medical condition: Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    8.0 10064930 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009909-25 Sponsor Protocol Number: KTvsMM1/09 Start Date*: 2009-05-05
    Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt
    Full Title: Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial
    Medical condition: Medical condition: moderate to severe non-proliferative retinopathy with diabetic cystoid macular edema.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004867-31 Sponsor Protocol Number: EOP 1012D Start Date*: 2005-04-12
    Sponsor Name:(OSI) Eyetech Pharmaceuticals, Inc
    Full Title: A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macug...
    Medical condition: Exudative Age Related Macular Degeneration (AMD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Prematurely Ended) AT (Completed) DE (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006312-30 Sponsor Protocol Number: MACPED-06-01 Start Date*: 2007-04-05
    Sponsor Name:Dept. of Ophthalmol, Semmelweis University
    Full Title: A phase IV non-randomized, uncontrolled, open-label, single-center trial to evaluate the safety and efficacy of Macugen (pegaptanib sodium) given by intravitreal injections every 6 weeks in patient...
    Medical condition: neovascular (wet) age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004106-25 Sponsor Protocol Number: EOP 1011E Start Date*: 2005-03-31
    Sponsor Name:(OSI) Eyetech, Inc
    Full Title: A Phase II randomised, dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium c...
    Medical condition: Exudative Age Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8 10025411 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001544-31 Sponsor Protocol Number: PATP1001 Start Date*: 2007-04-12
    Sponsor Name:Moorfields Eye Hospital
    Full Title: A randomised, double-masked, phase 3 study of the efficacy and safety of Avastin® (bevacizumab) intravitreal injections compared to best available therapy in subjects with choroidal neovasculariza...
    Medical condition: Exudative age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:10:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA